REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
Fernando Muñoz 1
Cristina Rodriguez 2
Javier Pérez Gisbert 3
Claudia Herrera de Guise 4
Isabel Vera Mendoza 5
Ana Gutiérrez-Casbas 6
Sabino Riestra 7
María Dolores Martín-Arranz 8
Pilar Martínez-Montiel 9
Vanesa Royo 10
Patricia Suárez 11
Esther García-Planella 12
Orlando Garcia-Bosch 13
Marisa Iborra 14
Jesus Aparicio 15
Ignacio Tagarro
Alonso Fernandez-Nistal
Carmen Montoto
Francisco Casellas 16
1 Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
2 Complejo Hospitalario de Navarra, Pamplona, Spain
3 Hospital Universitario de La Princesa, Madrid, Spain
4 Hospital Universitario Vall d'Hebron, Barcelona, Spain
5 Hospital Puerta de Hierro Majadahonda, Madrid, Spain
6 Hospital General Universitario de Alicante, Alicante, Spain
7 Hospital Universitario Central de Asturias, Oviedo, Spain
8 La Paz University Hospital, Madrid, Spain
9 Hospital Universitario 12 de Octubre, Madrid, Spain
10 Hospital Universitario Son Espases, Palma, Spain
11 Complejo Asistencial Universitario de León, León, Spain
12 Hospital de Sant Pau, Barcelona, Spain
13 Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain
14 La Fe University and Polytechnic Hospital, Valencia, Spain
15 Takeda Farmacéutica España S.A., Madrid, Spain
16 Hospital Universitari Vall d'Hebron, Barcelona, Spain
Session
IBD (Posters)
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]